Johnson & Johnson in Talks to Buy Protagonist Therapeutics
PositiveTechnology

Johnson & Johnson is in discussions to acquire Protagonist Therapeutics, a move that could significantly enhance their collaboration on a treatment for ulcerative colitis. This acquisition is important as it not only strengthens their existing partnership but also highlights J&J's commitment to expanding its portfolio in gastrointestinal therapies, potentially benefiting many patients suffering from this condition.
— Curated by the World Pulse Now AI Editorial System